TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prone Patient Positioning in Reducing Tumor Motion and Improving Breathing Reproduction in Patients With Lung Cancer Undergoing Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Measurable disease on the planning computed tomography (CT) scan~* Patients with lung cancer visible on fluoroscopic imaging or planning CT who are scheduled to receive external beam radiation treatment will be eligible for this study~Exclusion Criteria:~* Patients requiring continuous supplemental oxygen due to the requirement of spirometry during all imaging studies~* Pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (CT and 4D CT in supine and prone positioning) (Type: None): Patients undergo conventional CT scan and 4D CT scan in both supine and prone positioning before undergoing radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting, stable LDL-C ≥ 160 mg/dL~* Fasting, stable triglyceride \< 400 mg/dL~* BMI between 22 and 35 kg/m2, inclusive~* Females must be of non-child bearing potential~* Males of reproductive potential must agree to practice effective contraception throughout the study and for 3 months following infusion~Exclusion Criteria:~* Clinically significant endocrine, hematologic, renal, hepatic, pulmonary, uncontrolled psychiatric, or neurologic disease~* Cancer within 5 years prior to screening~* History of congestive heart failure or chronic heart failure~* Uncontrolled cardiac arrhythmias~* History of coronary heart disease~* Clinically significant abnormal baseline ECG~* History of additional risk factors for torsades de pointes~* Hepatitis B, C, or HIV positive~* Current diagnosis or known history of liver disease~* A marked baseline prolongation of QT/QTc interval~* Known history of fibromyalgia, myopathy, myositis, rhabdomyolysis, any unexplained muscle pain, or a creatine phosphokinase (CPK) \>3 x upper limit of normal (ULN) at screening~* Alanine aminotransferase, AST, GGT, or total bilirubin \>2 x ULN at screening~* Serum creatinine \> 1.5 mg/dL~* Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg on 2 occasions during screening~* Concomitant use of medications that prolongs the QT/QTc interval~* Treatment with lipid lowering therapy within 30 days prior to screening~* Use of investigational drug within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PRO-040201 (Type: EXPERIMENTAL): PRO-040201 with placebo control in each cohort
- Placebo (Type: PLACEBO_COMPARATOR): PRO-040201 with placebo control in each cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a previously untreated, T1 or T2, N0-N2b transorally resectable (as determined by the treating surgeon), histologically proven HPV positive, squamous cell carcinoma (SCC) of the oropharynx.~2. Eastern Cooperative Oncology Group (ECOG) PS 0-2.~3. Age \>/= 18 years.~4. Negative serum pregnancy test in females of childbearing potential.~5. Patients must sign a study-specific informed consent form prior to treatment.~Exclusion Criteria:~1. Evidence of distant metastases (below the clavicle) by clinical or radiographic examination.~2. Evidence of any other primary cancers or metastases. Evidence of deep soft-tissue or bony invasion, which would preclude TMIS by clinical and/or radiographic exam.~3. Contraindications to general anesthesia.~4. Patients who have had chemotherapy or radiotherapy to the oropharynx prior to entering the study.~5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~6. Patients with tumors whose resection would necessitate a free-tissue transfer for reconstruction of the surgical defect.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transoral Robotic Surgery (TORS) (Type: EXPERIMENTAL): Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm. Functional assessment performed at pre-treatment, within 1-4 weeks post-op from TORS (before adjuvant therapy), and after completion of treatment at the following time points: 6 months (±2 months), 12 months (±2 months), and 24 months (±6 months). Functional measures include video-fluoroscopic examination of swallowing (modified barium swallow \[MBS\] study) with administration of the Performance Status Scale-Head and Neck (PSS-HN) and MD Anderson Dysphagia Inventory (MDADI) questionnaire.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: MRI 3D UTE Hyper-Cones & ZTE for PET/MR Lung Attenuation Correction & for Lung Diagnostic Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* informed consent and signature~* clinical PET/CT planned and performed at Wagi site in Schlieren~* male or female patients~* from 18 to 80 years of age.~Exclusion Criteria:~- same exclusion criteria as for the clinical PET/CT exam (i.e. pregnant women).~Additional exclusion criteria:~- standard exclusion criteria for clinical MRI (evaluated by clinical standard determined by MRI questionnaire).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PET/MR (single arm) (Type: EXPERIMENTAL): PET and MR sequence acquisition on SIGNA PET/MR device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Provision of signed and dated informed consent form (ICF)~* ≥18 years old~* Diagnosis of r/r AML~* Subjects with CD33 positive leukemia cells~* Eastern Cooperative Oncology Group (ECOG) performance status ≤1~* Adequate organ function as defined in the protocol~* Donor specific antibody (DSA) to QN-023a: MFI \<= 2000~Key Exclusion Criteria:~* Allergic to drug used in this study~* Accept other anti-tumor drug within certain time of day 0 (first QN-023a dose infusion), time window and drug defined in the protocol.~* received systemic immunosuppressive therapy within 7 days of day 0, or likely to require systemic immunosuppressive therapy~* Acute Promyelocytic Leukemia (APL)~* Active central nervous system Leukemia.~* Uncontrolled, active clinically significant infection~* Clinically significant cardiovascular disease as defined in the protocol~* Known HIV infection, active Hepatitis B (HBV) or Hepatitis C (HCV) infection~* History of central nervous system (CNS) disease such as stroke, epilepsy.~* Females are pregnant or lactating~* Investigator-assessed presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QN-023a (Type: EXPERIMENTAL): QN-023a in adult subjects with r/r AML

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Keloid Tissue Bank

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have clinically confirmed diagnosis of keloid~2. Signed consent form; parent or a legal guardian should consent for children and those under age of 18.~3. Have at least one paraffin block of excess keloid tissue that has been removed in the past; or is planned to be removed in future.~4. Able and willing to undergo a keloid biopsy (optional)~5. Able and willing to undergo biopsy of their normal appearing skin (optional, minimum age 18).~Exclusion Criteria:~1. Individuals who are mentally challenged, who cannot consent to participate in this study.~2. Psychological Illness that may result in non-compliance with the procedure and the required follow up.~3. Known allergy to lidocaine or other local anesthetics.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with keloid (Type: None): All patients will have a clinical diagnosis of keloid and will consent to participate in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sentinel Node Detection in Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a high suspicion of a malignant ovarian tumour planned for exploratory laparotomy. Only when a malignancy is confirmed by frozen section, the SNs will be removed prior to proceeding with a complete staging procedure.~* Patients in whom the ovarian malignant tumour has already been resected and a second surgical procedure is planned to complete the staging procedure including lymph nodes.~* Mentally competent to give informed consent.~Exclusion Criteria:~* Previous vascular surgery of the aorta, caval vein, and/or iliac vessels.~* Previous lymphadenectomy of lymph node sampling in the iliac or para-aortal region.~* History of a malignant lymphoma.~* History of a malignant tumour in the abdominal cavity.~* Previous allergic reaction to blue dye.~* Pregnant or lactating patients.~* An allergy for human albumin.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sentinel node procedure. (Type: EXPERIMENTAL): Intervention: injection of blue dye and radioactive tracer (99mTc-nanocolloid or Nanocoll) in remains of the ovarian ligaments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nutrition, Growth and Development Among Very Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birth weight below 1,500 grams~* Written consent to participate from the parents~Exclusion Criteria:~* Congenital malformations~* Clinical syndromes known to affect growth and development~* Critical illness and short life expectancy~* If participants refuse to participate

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Participants in this group will receive nutrition from birth and during the hospital stay until discharge according to the routines of the participating institutions.
- Intervention (Type: ACTIVE_COMPARATOR): The participants in this group will receive increased supply of energy, protein, vitamin A, docosahexaenoic acid, and arachidonic acid from birth and during the hospital stay until discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infection~* age \> 18~* treatment with rilpivirine, elvitegravir, or dolutegravir (for exposed patients)~* treatment with none of these drugs (for non exposed patients)~* capacity of reading French language~Exclusion Criteria:~* drugs addiction (except for amyl nitriles (poppers) and cannabis)~* alcoholism~* co-infection with hepatitis C virus~* pregnant or breast feeding patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- exposition to the drugs (Type: None): patients treated with at least one of the following drugs: dolutegravir, elvitegravir and rilpivirine
- patients non exposed to the drugs (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of BAL Procedure With Ambu aScope 3 Large in Patients in an ICU Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years~* Clinical indication and eligible for a BAL procedure, as judged by the investigator~* Patients being admitted in the ICU at the investigational centre~* Provision of signed IC by subject, or subject's legal representative e.g. next of kin~Exclusion Criteria:~* Patients where BAL treatment cannot be clinically justified, judged by the investigator~* ETT \>7 mm and ≤8.5 mm in diameter~* Participating in other interventional clinical investigations or have previously participated in this investigation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aScope 3 Large (Type: OTHER): Bronchoscopic procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AnICD-10 schizophrenia diagnosis F20.0-F20.9.~* Contraception.~* A negative pregnancy test for women.~* No known allergy to any of the substances in the study medication~* Baseline QTc \< 450 milliseconds for men and \< 470 milliseconds for women~* S-potassium and s-magnesium within normal reference range.~* Suboptimally treated on current antipsychotic medication~* Stable dosage of antidepressants and mood stabilizers one month before the inclusion~* Signed informed consent and power of attorney~Exclusion Criteria:~* Withdrawal of consent~* QTc prolongation \>500 milliseconds during the study~* Patients with known clinical important cardiovascular disease~* Significant substance abuse~* Earlier partial or non-response in treatment or intolerability to sertindole or olanzapine.~* Calgary Depression Scale score ≥ 7~* Treatment that interferes with the metabolism of sertindole or olanzapine,~* Oxazepam, zopiclone or zolpidem treatment the last 48 hours before cognitive testing~* Prescription of not-allowed medication, or a change in dosage of antidepressant, or mood stabilizers in the study period~* Treatment with an anticholinergic after the first three weeks of the study~* Somatic illness, as judged by investigator, interfering with cognition~* Known risk of narrow angle glaucoma~* Treatment with electroconvulsive therapy (ECT) the last three months before inclusion, or treatment with ECT in the study period~* Treatment with clozapine or depot antipsychotics before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Sertindole (Type: ACTIVE_COMPARATOR): Sertindole 16-24 mg
- Olanzapine (Type: ACTIVE_COMPARATOR): Olanzapine 10-20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Multi-center Study on Total Hip Arthroplasty With E1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis~* Age between 20 - 75 at the time of operation~* Patients with limited co-morbidity -ASA I-III~* Patients must be able to understand instructions and be willing to return for follow up~Exclusion Criteria:~* In accordance with approved Absolute and Relative Contraindications for use in participating countries for E1 liner and Delta Ceramic and CoCr femoral head hip system System.~Absolute contraindications include: infection, sepsis, and osteomyelitis.~Relative contraindications include:~1. uncooperative patient or patient with neurologic disorders who are incapable of following directions,~2. osteoporosis,~3. metabolic disorders which may impair bone formation,~4. osteomalacia,~5. distant foci of infections which may spread to the implant site,~6. rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram, and~7. vascular insufficiency, muscular atrophy, or neuromuscular disease.~8. pregnancy

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BIOLOX delta head (Type: EXPERIMENTAL): Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~Biolox delta head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1.
- CoCr head (Type: ACTIVE_COMPARATOR): Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~CoCr head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced renal cell carcinoma with histology confirmation~* Grade III/IV AEs happen during first cycle of sunitinib 50mg/day 4 weeks on followed by 2 weeks of rest~* ECOG performance status 0 or 1~* Appropriate vital organ functions~Exclusion Criteria:~* Prior systemic treatment of mRCC~* Patients treated with any neoadjuvant or adjuvant systemic therapy~* Major surgery \<4 weeks or radiation therapy \<2 weeks of starting the study treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated~* Pregnant~* Allergic history to sunitinib

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib (Type: EXPERIMENTAL): Sunitinib malate, 12.5mg/capsule, 50mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues